Healthy Clinical Trial
Official title:
ContraTRAIN - a Validation Study of Contralateral Training Protocols
Verified date | May 2020 |
Source | Inland Norway University of Applied Sciences |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study aims to validate the use of contralateral designs in studies of effects of resistance exercise. It will recruit healthy young (18-35 years) individuals, which will be allocated to 4 experimental groups. In two of the experimental groups, 3x10 or 6x10 repetitions of heavy resistance exercise on one leg will be combined with no training of the other leg for 7 weeks. In the third group, 3x10 repetitions of heavy resistance exercise on one leg will be combined with 6x10 repetitions of heavy resistance exercise on the other leg for 7 weeks. In the fourth group, which serves as a control group, a period of no training (similar in length to the training period of groups 1-3; 7 weeks), before both legs will train 3x10 repetitions of heavy resistance exercise in an unilateral manner.
Status | Completed |
Enrollment | 38 |
Est. completion date | March 12, 2020 |
Est. primary completion date | March 12, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 35 Years |
Eligibility |
Inclusion Criteria: - Healthy Exclusion Criteria: - Smoking - Strength training more than 2 times per months for the last 6 months - Endurance training more than 3 hours per week - Adverse reactions to lidocaine - Consumption of supplements or medication affecting muscular adaptations to strength training |
Country | Name | City | State |
---|---|---|---|
Norway | Inland Norway University of Applied Sciences | Lillehammer |
Lead Sponsor | Collaborator |
---|---|
Inland Norway University of Applied Sciences | University of Birmingham |
Norway,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Muscle fiber area | Muscle cell cross-sectional area measured in biopsies from m. vastus lateralis using immunohistochemistry | Changes over the course of the intervention (0-10 weeks) | |
Secondary | Body mass composition | Body mass composition measured using Dual-energy X-ray absorptiometry (DXA) | Changes over the course of the intervention (0-10 weeks) | |
Secondary | Rate of muscle protein synthesis (%/day) | By ingesting deuterium we will label alanine to measure the rate of its incorporation into muscle proteins. This is done by collection of blood before, during and after, and a biopsy 3 days after deuterium ingestion to be analyzed with chromatography and mass spectrometry. Results will be reported as a rate of synthesis in %/day. | Mesured over 3 days in week 7 of the study | |
Secondary | M. vastus lateralis thickness | M. vastus lateralis thickness mesured by ultrasound | Changes over the course of the intervention (0-10 weeks) | |
Secondary | Unilateral leg press strength (1RM test) | The ability of muscles of the lower body to exert maximal force during dynamic movements in a leg press | Changes over the course of the intervention (0-10 weeks) | |
Secondary | Unilateral knee extension strength (1RM test) | The ability of muscles of the lower body to exert maximal force during dynamic movements in a knee extension | Changes over the course of the intervention (0-10 weeks) | |
Secondary | Barbell bench press muscle strength (1RM test) | The ability of muscles of the upper body to exert maximal force during dynamic movements in a bench press | Changes over the course of the intervention (0-10 weeks) | |
Secondary | Lying rowing muscle strength (1RM test) | The ability of muscles of the upper body to exert maximal force during dynamic movements in a lying row exercise | Changes over the course of the intervention (0-10 weeks) | |
Secondary | Unilateral lower body isokinetic muscle strength at 60 and 240 deg per second in a mechanical dynamometer (Humac NORM) | The ability of muscles of the lower body to exert maximal force during isokinetic movements | Changes over the course of the intervention (0-10 weeks) | |
Secondary | Unilateral lower body isometric muscle strength in a mechanical dynamometer (Humac NORM) | The ability of muscles of the lower body to exert maximal force during isometric contractions | Changes over the course of the intervention (0-10 weeks) | |
Secondary | One-legged cycling | Performance indicies measured during an incremental one-legged cycling test | Changes over the course of the intervention (0-10 weeks) | |
Secondary | Muscle phenotype | Muscle fiber type composition measured in biopsies from m. vastus lateralis using immunohistochemistry | Changes over the course of the intervention (0-10 weeks) | |
Secondary | Muscle cell biological traits | Muscle cell biological traits, including numbers of myonuclei, satelitte cells and capillaries, measured in biopsies from m. vastus lateralis using immunohistochemistry | Changes over the course of the intervention (0-10 weeks) | |
Secondary | Gene expression in skeletal muscle | RNA (e.g. messenger RNA, ribosomal RNA, microRNA, long non-coding RNA) abundances in m. vastus lateralis, measured both as single genes and at the level of the transcriptome | Changes over the course of the intervention (0-10 weeks) | |
Secondary | Protein abundances in skeletal muscle measured by western blot | Levels of proteins and their modification status (e.g. phosphorylation) in m. vastus lateralis, measured at the level of single proteins and at the level of the proteome | Changes over the course of the intervention (0-10 weeks) | |
Secondary | Hormones in blood | Levels of hormones in blood | Changes over the course of the intervention (0-10 weeks) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |